中文摘要
肾乳头状细胞癌(KIRP)是一种低度恶性的肾细胞癌。KIRP的治疗仍面临巨大挑战。细胞分裂周期相关蛋白3(CDCA3)参与人体生理和病理过程。
然而,其在KIRP中的作用尚未明确。在此,我们采用综合生物信息学方法评估了CDCA3在KIRP中的预后价值。从在线数据库获取KIRP中CDCA3的表达数据。通过基因本体论和京都基因与基因组百科全书通路富集分析,鉴定并评估了CDCA3高表达组与低表达组之间的差异表达基因。进行基因集富集分析以阐明两组之间的功能和通路差异。采用单样本GSEA方法分析免疫细胞,比较CDCA3低表达组与高表达组之间免疫细胞浸润的差异。构建蛋白质-蛋白质相互作用网络并鉴定枢纽基因。使用UALCAN分析KIRP组织中CDCA3 mRNA表达水平与临床病理参数之间的关联。通过ROC分析评估CDCA3对KIRP的诊断效能。采用Logistic回归分析临床病理特征与CDCA3表达之间的关系。
我们的结果表明,CDCA3 mRNA高表达与KIRP患者的部分临床病理参数显著相关。CDCA3 mRNA高表达与较短的总生存期、无进展间期和疾病特异性生存期相关。
综上所述,CDCA3是开发抗KIRP治疗药物的潜在靶点,也是一种有效的预后标志物。
展开英文摘要原文
Kidney renal papillary cell carcinoma (KIRP) is a type of low-grade malignant renal cell carcinoma. Huge challenges remain in the treatment of KIRP. Cell division cycle associated 3 (CDCA3) participates in human physiological and pathological processes.
However, its role in KIRP has not been established. Here, we evaluated the prognostic value of CDCA3 in KIRP using a comprehensive bioinformatics approach. Data for CDCA3 expression in KIRP were obtained from online database. Different expression genes between high and low CDCA3 expression groups were identified and evaluated by performing Gene ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses. A gene set enrichment analysis was performed to elucidate the function and pathway differences between the different.
Differences in immune cell infiltration between low and high CDCA3 expression groups were analyzed by a single-sample GSEA method for immune cells. A protein-protein interaction network was generated and hub genes were identified.
UALCAN was used to analyze associations between the mRNA expression levels of CDCA3 in KIRP tissues with clinicopathologic parameters. The diagnostic efficacy of CDCA3 for KIRP was analyzed by ROC analysis. Logistic regression was used to analyze relationships between the clinicopathological characteristics and CDCA3 expression.
Our results indicated that high CDCA3 mRNA expression is significantly associated with some clinicopathologic parameters in KIRP patients High CDCA3 mRNA expression associated with a shorter overall survival, progression-free interval, and disease-special survival. Taken together, CDCA3 is a potential target for the development of anti-KIRP therapeutics and is an efficient prognostic marker.
论文信息
- 作者
- Li H、Li M、Yang C、Guo F、Deng S、Li L、Ma T、Yan J
- 第一作者单位
- Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.China
- 通讯作者单位
- Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China.China
- 文献类型
- 非美国政府资助研究
- 期刊
- Aging2021 Dec 14